Abeona Therapeutics (ABEO) Operating Leases (2019 - 2026)

Abeona Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• In Q1 2026, Operating Leases fell 6.47% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 6.47% YoY), while the FY2025 annual figure was $4.1 million, up 24.74% from the prior year.
• Operating Leases for Q1 2026 stood at $3.8 million, down from $4.1 million in the prior quarter.
• The five-year high for Operating Leases was $9.1 million in Q1 2022, with the low at $3.0 million in Q2 2024.
• The 5-year median for Operating Leases is $4.1 million (2025), against an average of $5.0 million.
• The sharpest annual moves came in 2022 and 2023: Operating Leases soared 86.72% in 2022, then tumbled 51.25% in 2023.
• Abeona Therapeutics' Operating Leases stood at $5.9 million in 2022, then dropped by 24.8% to $4.4 million in 2023, then fell by 25.9% to $3.3 million in 2024, then gained by 24.74% to $4.1 million in 2025, then decreased by 6.27% to $3.8 million in 2026.
• Business Quant data shows ABEO's Operating Leases at $3.8 million in Q1 2026, $4.1 million in Q4 2025, and $4.3 million in Q3 2025.